Noma epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Changes made per Mahshid's request)
 
Line 10: Line 10:
{{WS}}
{{WS}}
[[Category:Disease]]
[[Category:Disease]]
[[Category:Infectious disease]]
 
[[Category:Needs overview]]
[[Category:Needs overview]]
[[Category:Bacterial diseases]]
[[Category:Bacterial diseases]]

Latest revision as of 18:12, 18 September 2017

Noma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Noma from other Diseases

Epidemiology and Demographics

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Noma epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Noma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Noma epidemiology and demographics

CDC on Noma epidemiology and demographics

Noma epidemiology and demographics in the news

Blogs on Noma epidemiology and demographics

Directions to Hospitals Treating Noma

Risk calculators and risk factors for Noma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Epidemiology and Demographics

The disease is associated with high morbidity and mortality[1] (of around 80 per cent) and mainly affects children under the age of twelve in the poorest countries of Africa. Children in Asia and some countries of South America are also affected. Most children who get the disease are between the ages of two and six years old. The WHO estimates that 500,000 people are affected with 100,000 new cases each year[2]. Estimates claim that 80 - 90% of noma cases die from the disease.

References

  1. Barmes DE, Enwonwu CO, Leclercq MH, Bourgeois D, Falkler WA. The need for action against oro-facial gangrene (noma). Trop Med Int Health 1997; 2: 1111-1114.
  2. Bourgeois DM, Leclercq MH. The World Health Organization initiative on noma. Oral Dis 1999; 5: 172-174.

Template:WH Template:WS